Compare Rent the Runway Inc (RENT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rent the Runway Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Rent the Runway Inc trades at $1.71 (market cap $61.07M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 123.1× Rent the Runway Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RENT | SYRE | |
|---|---|---|
Market Cap | $61.07M | $7.52B |
Volume | 80,595 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $108.92 |
52-Week Low | $1.55 | $22.18 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $228.07M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rent the Runway (RENT) trades at $1.71, down 6.56% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with a gross margin of 74.73%, though net income was -$69.90M. Recent news includes a CEO appointment and multiple law firm investigations into investor claims.
The outlook remains challenging with negative equity and high debt, but improving margins and projected 2026 profitability offer potential. Risks include legal scrutiny and financial leverage, while analyst consensus is cautiously optimistic with 42% buy ratings. Stock performance hinges on execution of turnaround efforts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
